List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2386146/publications.pdf Version: 2024-02-01

		57758	71685
222	7,974	44	76
papers	citations	h-index	g-index
231	231	231	11609
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Potential association between COVID-19 mortality and health-care resource availability. The Lancet Global Health, 2020, 8, e480.	6.3	593
2	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13109-13113.	7.1	422
3	Antibodies Against Immune Checkpoint Molecules RestoreÂFunctions of Tumor-Infiltrating T Cells in HepatocellularÂCarcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	1.3	309
4	Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. Journal of Infectious Diseases, 2020, 221, 1677-1687.	4.0	182
5	Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation, 2012, 18, 290-297.	2.4	177
6	Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis. Hepatology, 2016, 64, 350-359.	7.3	166
7	Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus. Gastroenterology, 2014, 146, 1775-1783.	1.3	158
8	Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral Research, 2015, 123, 120-131.	4.1	156
9	Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. Trends in Microbiology, 2017, 25, 573-584.	7.7	151
10	Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut, 2012, 61, 1330-1339.	12.1	150
11	SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research, 2022, 32, 322-324.	12.0	148
12	Ribavirin Inhibits <i>In Vitro</i> Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon. Antimicrobial Agents and Chemotherapy, 2014, 58, 267-273.	3.2	126
13	PD-L1, Galectin-9 and CD8 ⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncolmmunology, 2017, 6, e1273309.	4.6	117
14	The global epidemiology of hepatitis E virus infection: A systematic review and metaâ€analysis. Liver International, 2020, 40, 1516-1528.	3.9	115
15	Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. Experimental Biology and Medicine, 2014, 239, 105-115.	2.4	110
16	Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 407-431.	4.5	103
17	Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology, 2014, 61, 746-754.	3.7	97
18	Hepatitis E Virus Infects Neurons and Brains. Journal of Infectious Diseases, 2017, 215, 1197-1206.	4.0	94

#	Article	IF	CITATIONS
19	Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology, 2012, 55, 1673-1683.	7.3	91
20	Secreted Factors of Human Liver-Derived Mesenchymal Stem Cells Promote Liver Regeneration Early After Partial Hepatectomy. Stem Cells and Development, 2012, 21, 2410-2419.	2.1	90
21	Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clinical Gastroenterology and Hepatology, 2022, 20, e573-e582.	4.4	84
22	Matrix Metalloproteinases (MMPs) in Liver Diseases. Journal of Clinical and Experimental Hepatology, 2017, 7, 367-372.	0.9	83
23	The global burden of hepatitis E outbreaks: a systematic review. Liver International, 2017, 37, 19-31.	3.9	80
24	The impact of COVID-19 pandemic outbreak on education and mental health of Chinese children aged 7–15 years: an online survey. BMC Pediatrics, 2021, 21, 95.	1.7	79
25	Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncolmmunology, 2015, 4, e1008355.	4.6	78
26	Action and function of Wnt∫î²-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 419-431.	5.1	66
27	Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2834-2848.	3.2	64
28	Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science Signaling, 2017, 10, .	3.6	64
29	Remodeling of the gut microbiome during Ramadan-associated intermittent fasting. American Journal of Clinical Nutrition, 2021, 113, 1332-1342.	4.7	64
30	Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology, 2022, 75, 419-429.	7.3	64
31	Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus. Gastroenterology, 2013, 144, 761-770.	1.3	63
32	RIGâ€l is a key antiviral interferonâ€stimulated gene against hepatitis E virus regardless of interferon production. Hepatology, 2017, 65, 1823-1839.	7.3	63
33	Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Reviews in Medical Virology, 2013, 23, 295-304.	8.3	61
34	Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells, 2020, 9, 121.	4.1	60
35	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by metaâ€analysis: Focusing on the nonâ€overlap groups. Liver International, 2022, 42, 277-287.	3.9	60
36	SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene, 2015, 34, 5055-5068.	5.9	57

#	Article	IF	CITATIONS
37	Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV. Scientific Reports, 2016, 6, 25482.	3.3	56
38	IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFNâ€stimulated genes. FASEB Journal, 2016, 30, 3352-3367.	0.5	54
39	Epigenome-Wide Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic Steatosis. Gastroenterology, 2017, 153, 1096-1106.e2.	1.3	52
40	PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. Virulence, 2018, 9, 83-98.	4.4	51
41	Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis, 2013, 34, 2330-2340.	2.8	50
42	Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research, 2016, 133, 41-49.	4.1	50
43	Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 117-125.	7.4	50
44	LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nature Communications, 2020, 11, 1961.	12.8	49
45	Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. Journal of Molecular Medicine, 2009, 87, 713-722.	3.9	46
46	GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells <i>ex vivo</i> . OncoImmunology, 2015, 4, e1051297.	4.6	45
47	Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transplantation, 2011, 17, 596-609.	2.4	44
48	Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. Lancet Microbe, The, 2020, 1, e151.	7.3	43
49	TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 443-464.	4.5	43
50	GITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 1111-1124.	5.1	42
51	Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
52	Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. Cytotherapy, 2013, 15, 1352-1361.	0.7	40
53	IRF-1, RIG-I and MDA5 display potent antiviral activities against norovirus coordinately induced by different types of interferons. Antiviral Research, 2018, 155, 48-59.	4.1	40
54	Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. Gastroenterology, 2017, 153, 1133-1147.	1.3	39

#	Article	IF	CITATIONS
55	Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic InfectionÂin Organ Recipient. Gastroenterology, 2018, 154, 1199-1201.	1.3	38
56	Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Molecular and Cellular Biochemistry, 2007, 304, 315-323.	3.1	37
57	Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia, 2016, 18, 711-723.	5.3	37
58	The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology, 2018, 67, 2096-2112.	7.3	37
59	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports, 2019, 9, 10677.	3.3	37
60	Chronic hepatitis E: Advancing research and patient care. Journal of Hepatology, 2022, 77, 1109-1123.	3.7	37
61	Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. British Journal of Cancer, 2015, 112, 1911-1920.	6.4	36
62	TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. Virus Research, 2018, 253, 28-37.	2.2	36
63	6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling. Antiviral Research, 2018, 156, 92-101.	4.1	36
64	Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication. Antiviral Research, 2019, 167, 35-44.	4.1	35
65	Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. Nature Communications, 2021, 12, 2830.	12.8	35
66	The genetic divergences of codon usage shed new lights on transmission of hepatitis E virus from swine to human. Infection, Genetics and Evolution, 2019, 68, 23-29.	2.3	34
67	Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology, 2021, 564, 33-38.	2.4	34
68	Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncológica, 2008, 47, 135-144.	1.8	33
69	Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation. Stem Cell Reports, 2014, 3, 606-619.	4.8	33
70	Anti-Tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0127967.	2.5	32
71	Rotavirus in Organ Transplantation: Drug-Virus-Host Interactions. American Journal of Transplantation, 2015, 15, 585-593.	4.7	31
72	Rhesus macaques persistently infected with hepatitis E shed virus into urine. Journal of Hepatology, 2016, 64, 1446-1447.	3.7	30

#	Article	IF	CITATIONS
73	Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine, 2018, 36, 122-130.	6.1	30
74	Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis, 2019, 40, 145-154.	2.8	30
75	RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry, 2019, 63, 24-31.	1.9	29
76	AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?. Expert Opinion on Biological Therapy, 2011, 11, 315-327.	3.1	28
77	Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids. Scientific Reports, 2018, 8, 8341.	3.3	28
78	Recapitulating hepatitis E virus–host interactions and facilitating antiviral drug discovery in human liver–derived organoids. Science Advances, 2022, 8, eabj5908.	10.3	28
79	A dynamic perspective of RNAi library development. Trends in Biotechnology, 2012, 30, 206-215.	9.3	27
80	Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of Viral Hepatitis, 2016, 23, 294-304.	2.0	27
81	Errors in translational decoding: tRNA wobbling or misincorporation?. PLoS Genetics, 2019, 15, e1008017.	3.5	27
82	Distinct Antiviral Potency of Sofosbuvir Against Hepatitis CÂand E Viruses. Gastroenterology, 2016, 151, 1251-1253.	1.3	26
83	Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacologica Sinica, 2007, 28, 1996-2004.	6.1	25
84	Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. FEBS Letters, 2011, 585, 1025-1030.	2.8	25
85	Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15193-15204.	1.8	25
86	Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transplantation, 2014, 20, 261-269.	2.4	24
87	DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells. International Journal of Molecular Medicine, 2014, 33, 17-24.	4.0	24
88	Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Archives of Virology, 2017, 162, 2989-2996.	2.1	24
89	A functional variant in the miRâ€142 promoter modulating its expression and conferring risk of Alzheimer disease. Human Mutation, 2019, 40, 2131-2145.	2.5	23
90	Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Research, 2020, 184, 104967.	4.1	23

#	Article	IF	CITATIONS
91	Guanylate-binding protein 2 orchestrates innate immune responses against murine norovirus and is antagonized by the viral protein NS7. Journal of Biological Chemistry, 2020, 295, 8036-8047.	3.4	23
92	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary Pharmacology and Therapeutics, 2021, 53, 432-442.	3.7	23
93	Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. Transplantation, 2022, 106, 2068-2075.	1.0	23
94	Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral Research, 2015, 124, 11-19.	4.1	22
95	Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. Scientific Reports, 2018, 8, 12471.	3.3	22
96	Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB Journal, 2019, 33, 1008-1019.	0.5	22
97	Telaprevir/boceprevir era: From bench to bed and back. World Journal of Gastroenterology, 2012, 18, 6183.	3.3	22
98	Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-1±. Liver Transplantation, 2010, 16, 520-526.	2.4	21
99	Noncanonical Antiviral Mechanisms of ISGs: Dispensability of Inducible Interferons. Trends in Immunology, 2017, 38, 1-2.	6.8	21
100	Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
101	The Burden of Human Papillomavirus and <i>Chlamydia trachomatis</i> Coinfection in Women: A Large Cohort Study in Inner Mongolia, China. Journal of Infectious Diseases, 2019, 219, 206-214.	4.0	21
102	Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. Hepatology, 2022, 76, 788-802.	7.3	21
103	Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert Opinion on Biological Therapy, 2009, 9, 713-724.	3.1	20
104	Drug screening identifies gemcitabine inhibiting rotavirus through alteration of pyrimidine nucleotide synthesis pathway. Antiviral Research, 2020, 180, 104823.	4.1	20
105	Unique challenges to control the spread of COVID-19 in the Middle East. Journal of Infection and Public Health, 2020, 13, 1247-1250.	4.1	20
106	Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients. International Journal of Infectious Diseases, 2021, 102, 375-380.	3.3	20
107	Rotavirus-related systemic diseases: clinical manifestation, evidence and pathogenesis. Critical Reviews in Microbiology, 2021, 47, 580-595.	6.1	20
108	A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Drugs in R and D, 2021, 21, 273-283.	2.2	20

#	Article	IF	CITATIONS
109	Virus–drug interactions—molecular insight into immunosuppression and HCV. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 355-362.	17.8	19
110	Chronic hepatitis E in solid-organ transplantation. Current Opinion in Infectious Diseases, 2014, 27, 303-308.	3.1	19
111	The Interplay between Host Innate Immunity and Hepatitis E Virus. Viruses, 2019, 11, 541.	3.3	19
112	Rotavirus Infection and Cytopathogenesis in Human Biliary Organoids Potentially Recapitulate Biliary Atresia Development. MBio, 2020, 11, .	4.1	19
113	Hepatitis E virus infection activates NODâ€like receptor family pyrin domainâ€containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology, 2022, 75, 196-212.	7.3	19
114	Mono- and combinational drug therapies for global viral pandemic preparedness. IScience, 2022, 25, 104112.	4.1	19
115	Genotype-specific acquisition, evolution and adaptation of characteristic mutations in hepatitis E virus. Virulence, 2018, 9, 121-132.	4.4	18
116	FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis. Antiviral Research, 2019, 170, 104588.	4.1	17
117	Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. Scientific Reports, 2021, 11, 23465.	3.3	17
118	Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China. Scientific Reports, 2017, 7, 9595.	3.3	16
119	Opposing Effects of Nitazoxanide on Murine and Human Norovirus. Journal of Infectious Diseases, 2017, 216, 780-782.	4.0	16
120	Prevalence of human papillomavirus infection in women in the Autonomous Region of Inner Mongolia: A populationâ€based study of a Chinese ethnic minority. Journal of Medical Virology, 2018, 90, 148-156.	5.0	16
121	Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in Medical Virology, 2019, 29, e2075.	8.3	16
122	Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients. Transplantation, 2019, 103, 929-937.	1.0	16
123	Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context. Journal of Infectious Diseases, 2020, 222, 695-696.	4.0	16
124	MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. Antiviral Research, 2020, 176, 104743.	4.1	16
125	Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review. European Journal of Clinical Investigation, 2021, 51, e13479.	3.4	16
126	cGAS-STING effectively restricts murine norovirus infection but antagonizes the antiviral action of N-terminus of RIG-I in mouse macrophages. Gut Microbes, 2021, 13, 1959839.	9.8	16

#	Article	IF	CITATIONS
127	Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations. Lancet Microbe, The, 2022, 3, e325-e326.	7.3	16
128	Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested caseâ€control study. Liver International, 2019, 39, 2291-2300.	3.9	15
129	Directâ€acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and metaâ€analysis. Transplant Infectious Disease, 2019, 21, e13047.	1.7	15
130	Recapitulating Cholangiopathy-Associated Necroptotic Cell Death InÂVitro Using Human Cholangiocyte Organoids. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 541-564.	4.5	15
131	Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. Molecular Medicine, 2015, 21, 792-802.	4.4	14
132	Norovirus and rotavirus infections in children less than five years of age hospitalized with acute gastroenteritis in Indonesia. Archives of Virology, 2019, 164, 1515-1525.	2.1	14
133	No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients. Hepatology, 2019, 69, 1846-1847.	7.3	14
134	Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 77-88.	3.9	14
135	Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research, 2017, 140, 1-12.	4.1	13
136	Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine. Frontiers in Cellular and Infection Microbiology, 2018, 8, 249.	3.9	13
137	Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus. Journal of Viral Hepatitis, 2019, 26, 183-190.	2.0	13
138	Revisiting the estimation of hepatitis D global prevalence. Journal of Hepatology, 2020, 73, 1279-1280.	3.7	13
139	Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. Transplantation, 2021, 105, 2362-2373.	1.0	13
140	Outcome of a screening program for the prevention of neonatal early-onset group B Streptococcus infection: a population-based cohort study in Inner Mongolia, China. Journal of Medical Microbiology, 2019, 68, 803-811.	1.8	13
141	A novel strategy for cancer gene therapy: RNAi. Science Bulletin, 2006, 51, 1145-1151.	1.7	12
142	Significance of continuous rotavirus and norovirus surveillance in Indonesia. World Journal of Pediatrics, 2018, 14, 4-12.	1.8	12
143	Hepatitis E virus infection in HIVâ€infected patients: A large cohort study in Yunnan province, China. Journal of Medical Virology, 2018, 90, 1121-1127.	5.0	12
144	Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?. Trends in Immunology, 2020, 41, 851-853.	6.8	12

#	Article	IF	CITATIONS
145	Prevalence and clinical features of hepatitis E virus infection in pregnant women: A large cohort study in Inner Mongolia, China. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101536.	1.5	12
146	Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses. Clinical Infectious Diseases, 2021, 73, 554-555.	5.8	12
147	Effects of intermittent fasting on liver physiology and metabolism in mice. Experimental and Therapeutic Medicine, 2021, 22, 950.	1.8	12
148	In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. International Journal of Peptide Research and Therapeutics, 2022, 28, 28.	1.9	12
149	Direct-acting antiviral therapy for hepatitis E virus?. The Lancet Gastroenterology and Hepatology, 2017, 2, 154-155.	8.1	11
150	Immunity against hepatitis E virus infection: Implications for therapy and vaccine development. Reviews in Medical Virology, 2018, 28, e1964.	8.3	11
151	The Eukaryotic Translation Initiation Factor 4F Complex Restricts Rotavirus Infection via Regulating the Expression of IRF1 and IRF7. International Journal of Molecular Sciences, 2019, 20, 1580.	4.1	11
152	Efficacy of Different Endoscopic Stents in the Management of Postoperative Biliary Strictures. Journal of Clinical Gastroenterology, 2019, 53, 418-426.	2.2	11
153	Lipopolysaccharide restricts murine norovirus infection in macrophages mainly through NF-kB and JAK-STAT signaling pathway. Virology, 2020, 546, 109-121.	2.4	11
154	Hepatitis E virus seroprevalence in pets in the Netherlands and the permissiveness of canine liver cells to the infection. Irish Veterinary Journal, 2020, 73, 6.	2.1	11
155	Estimating the global prevalence of hepatitis E virus in swine and pork products. One Health, 2022, 14, 100362.	3.4	11
156	Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. Hepatology, 2011, 53, 1400-1401.	7.3	10
157	Multipotent mesenchymal stromal cells in liver cancer: Implications for tumor biology and therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 439-445.	7.4	10
158	Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific. Archives of Virology, 2015, 160, 435-439.	2.1	10
159	Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clinical and Experimental Gastroenterology, 2017, Volume 10, 203-209.	2.3	9
160	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis, 2019, 40, 155-163.	2.8	9
161	The biological process of lysineâ€tRNA charging is therapeutically targetable in liver cancer. Liver International, 2021, 41, 206-219.	3.9	9
162	A multiâ€regional, hierarchicalâ€tier mathematical model of the spread and control of COVIDâ€19 epidemics from epicentre to adjacent regions. Transboundary and Emerging Diseases, 2022, 69, 549-558.	3.0	9

#	Article	IF	CITATIONS
163	Mathematical analysis of a human papillomavirus transmission model with vaccination and screening. Mathematical Biosciences and Engineering, 2020, 17, 5449-5476.	1.9	9
164	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary Pharmacology and Therapeutics, 2021, 53, 432-442.	3.7	9
165	Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. Journal of Molecular Medicine, 2022, 100, 471-484.	3.9	9
166	Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. Antiviral Research, 2022, 197, 105228.	4.1	9
167	Antiviral or proviral action of mycophenolic acid in hepatitis B infection?. Hepatology, 2012, 56, 1586-1587.	7.3	8
168	Gene Therapies for Hepatitis C Virus. Advances in Experimental Medicine and Biology, 2015, 848, 1-29.	1.6	8
169	Genetically Engineered Bacteria for Treating Human Disease. Trends in Pharmacological Sciences, 2017, 38, 763-764.	8.7	8
170	Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene, 2018, 675, 157-164.	2.2	8
171	The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection. Veterinary Research Communications, 2018, 42, 309-313.	1.6	8
172	Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. Journal of Infection, 2019, 79, 262-276.	3.3	8
173	Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling. Molecular Cancer Research, 2019, 17, 521-531.	3.4	8
174	Lipid droplets and their interactions with other organelles in liver diseases. International Journal of Biochemistry and Cell Biology, 2021, 133, 105937.	2.8	8
175	Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1. Archives of Virology, 2021, 166, 2005-2010.	2.1	8
176	Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids. EBioMedicine, 2022, 81, 104132.	6.1	8
177	A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation. Digestive Diseases and Sciences, 2018, 63, 2653-2661.	2.3	7
178	Chronic hepatitis E in an immunocompetent patient. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, e66-e68.	1.5	7
179	Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. Trends in Pharmacological Sciences, 2020, 41, 501-503.	8.7	7
180	Mathematical modelling and projecting the second wave of COVID-19 pandemic in Europe. Journal of Epidemiology and Community Health, 2021, 75, 601-603.	3.7	7

#	Article	IF	CITATIONS
181	Identification of Rotavirus Strains Causing Diarrhoea in Children under Five Years of Age in Yogyakarta, Indonesian. The Malaysian Journal of Medical Sciences, 2017, 24, 68-77.	0.5	7
182	Targeting Viral Polymerase for Treating Hepatitis E Infection: How Far Are We?. Gastroenterology, 2016, 150, 1690.	1.3	6
183	Murine norovirus replicase augments RIG-I-like receptors-mediated antiviral interferon response. Antiviral Research, 2020, 182, 104877.	4.1	6
184	Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infectious Diseases, 2020, 7, ofaa107.	0.9	6
185	The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models. International Journal of Antimicrobial Agents, 2021, 58, 106383.	2.5	6
186	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	8.9	6
187	The Challenges of Long-Term Transcriptional Gene Silencing by RNA Viruses. Trends in Biochemical Sciences, 2018, 43, 649-650.	7.5	5
188	A simplified qPCR method revealing tRNAome remodeling upon infection by genotype 3 hepatitis E virus. FEBS Letters, 2020, 594, 2005-2015.	2.8	5
189	Estimating the burden and modeling mitigation strategies of pork-related hepatitis E virus foodborne transmission in representative European countries. One Health, 2021, 13, 100350.	3.4	5
190	Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps. AIMS Mathematics, 2022, 7, 9288-9310.	1.6	5
191	Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers, 2021, 13, 2499.	3.7	4
192	Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. Cell Death Discovery, 2021, 7, 293.	4.7	4
193	Highâ€dose vitamin D metabolite delivery inhibits breast cancer metastasis. Bioengineering and Translational Medicine, 2022, 7, e10263.	7.1	4
194	Sensitivity analysis and optimal treatment control for a mathematical model of Human Papillomavirus infection. AIMS Mathematics, 2020, 5, 2646-2670.	1.6	4
195	Overestimation of hematopoietic stem cell frequencies in human liver grafts. Hepatology, 2013, 57, 2547-2549.	7.3	3
196	Should Nivolumab-Induced Colitis Be Treated by Infliximab?. Clinical Gastroenterology and Hepatology, 2017, 15, 1637.	4.4	3
197	Mushroom poisoning: an overlooked cause of acute liver injury in China. Liver International, 2017, 37, 468-469.	3.9	3
198	Phylogenetic and immunoinformatic analysis of VP4, VP7, and NSP4 genes of rotavirus strains circulating in children with acute gastroenteritis in Indonesia. Journal of Medical Virology, 2019, 91, 1776-1787.	5.0	3

#	Article	IF	CITATIONS
199	Tracing genetic signatures of batâ€ŧoâ€human coronaviruses and early transmission of North American SARSâ€CoVâ€2. Transboundary and Emerging Diseases, 2021, , .	3.0	3
200	Hepatitis D. Chinese Medical Journal, 2022, Publish Ahead of Print, .	2.3	3
201	Kidney Organoids Are Capable of Forming Tumors, but Not Teratomas. Stem Cells, 2022, 40, 577-591.	3.2	3
202	Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions. Archives of Virology, 2022, 167, 1125-1130.	2.1	3
203	HEV prevalence and potential risk factors in a large multi-ethnic youth cohort in China. Virology Journal, 2021, 18, 3.	3.4	2
204	The dynamics of hepatitis delta virus prevalence and its potential association with hepatitis B virus vaccination. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101677.	1.5	2
205	New targets for treatment against HCV infection. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 505-515.	2.4	1
206	Virus–host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut, 2015, 64, 852-853.	12.1	1
207	Cytoplasmic rods and rings in mycophenolic acid treatment. Liver International, 2017, 37, 1742-1743.	3.9	1
208	Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits. BioMed Research International, 2018, 2018, 1-6.	1.9	1
209	Sofosbuvir directly promotes the clonogenic capability of human hepatocellular carcinoma cells. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e79-e81.	1.5	1
210	Evolutionarily missing and conserved tRNA genes in human and avian. Infection, Genetics and Evolution, 2020, 85, 104460.	2.3	1
211	Letter to the Editor: High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia. Hepatology, 2021, 74, 2920-2921.	7.3	1
212	Probing the direct effects of antiretroviral drugs on hepatitis EÂvirus replication in cell culture models. Liver International, 2022, 42, 716-717.	3.9	1
213	Reply to Sayed and Meuleman. Journal of Infectious Diseases, 2017, 216, 920-921.	4.0	0
214	Reply to Wang et al. Journal of Infectious Diseases, 2017, 215, 1341-1342.	4.0	0
215	Quality of Symptom-Based Diagnosis of Rotavirus Infection Based on Mathematical Modeling. Advances in Intelligent Systems and Computing, 2019, , 555-566.	0.6	0
216	Co-occurrence of heterozygous mutations in COL1A1 and SERPINF1 in a high-risk pregnancy complicated by osteogenesis imperfecta. Journal of Genetics, 2019, 98, 1.	0.7	0

#	Article	IF	CITATIONS
217	2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705. Archives of Virology, 2020, 165, 2605-2613.	2.1	Ο
218	Author response to Letter to the Editor: Hepatitis E prevalence in indigenous communities from Western Brazilian Amazon. Liver International, 2021, 41, 234-234.	3.9	0
219	Anti-diabetic drugs, insulin and metformin, have no direct interaction with hepatitis C virus infection or anti-viral interferon response. AIMS Molecular Science, 2014, 1, 49-58.	0.5	Ο
220	The Global Burden of Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
221	Distinct effectiveness in containing COVID-19 epidemic: Comparative analysis of two cities in China by mathematical modeling. PLOS Clobal Public Health, 2021, 1, e0000043.	1.6	Ο
222	A proposed disease classification system for duck viral hepatitis. Poultry Science, 2022, , 102042.	3.4	0